Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study

Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study

Abstract Background Advanced lung adenocarcinoma (LAC) is one of the most lethal malignancies worldwide. The aim of this study was to evaluate the global survival in a real-life cohort of patients with LAC harboring driver genetic alterations. Methods A series of 1282 consecutive Sardinian LAC patie...

Full description

Bibliographic Details
Main Authors:	Panagiotis Paliogiannis, Maria Colombino, Maria Cristina Sini, Antonella Manca, Milena Casula, Grazia Palomba, Marina Pisano, Valentina Doneddu, Angelo Zinellu, Davide Santeufemia, Sardinian Lung Cancer (SLC) Study Group, Giovanni Sotgiu, Antonio Cossu, Giuseppe Palmieri
Format:	Article
Language:	English
Published:	BMC 2022-01-01
Series:	BMC Pulmonary Medicine
Subjects:	Lung adenocarcinoma Mutation analysis EGFR KRAS BRAF ALK and MET rearrangements
Online Access:	https://doi.org/10.1186/s12890-021-01803-0

Similar Items

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
by: Maria Colombino, et al.
Published: (2019-11-01)

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
by: Pranshu eBansal, et al.
Published: (2016-05-01)

Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma
by: Milena Casula, et al.
Published: (2023-03-01)

Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation
by: Bo Zhang, et al.
Published: (2022-09-01)

Incidence and patterns of <it>ALK</it> FISH abnormalities seen in a large unselected series of lung carcinomas
by: Dai Zunyan, et al.
Published: (2012-12-01)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01)

Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant  Organ Metastasis in Non-small Cell Lung Cancer
by: Ge GAO, et al.
Published: (2018-07-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Didik Setyo Heriyanto, et al.
Published: (2022-12-01)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
by: Gang Shen, et al.
Published: (2021-12-01)

Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review
by: Filippo Tommaso Gallina, et al.
Published: (2022-04-01)

ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey
by: Gulden Diniz, et al.
Published: (2022-01-01)

Comparison of <i>BRAF</i> Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients
by: Maria Colombino, et al.
Published: (2020-07-01)

Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach
by: Antonella Manca, et al.
Published: (2019-08-01)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
by: Shoko Sonobe Shimamura, et al.
Published: (2022-03-01)

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer
by: Till Plönes, et al.
Published: (2016-01-01)

Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy
by: Lin JIANG, et al.
Published: (2022-07-01)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
by: Chiara Pisano, et al.
Published: (2022-01-01)

Multivariate Risk Analysis of RAS, BRAF and EGFR Mutations Allelic Frequency and Coexistence as Colorectal Cancer Predictive Biomarkers
by: Adriana Ionescu, et al.
Published: (2022-06-01)

Biomarkers that currently effect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1 and KRAS
by: Grzegorz Janusz Korpanty, et al.
Published: (2014-08-01)

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer
by: Rodolfo Chicas-Sett, et al.
Published: (2023-01-01)

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
by: Sara S. Fois, et al.
Published: (2021-01-01)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
by: Edouard Dantoing, et al.
Published: (2021-06-01)

Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma
by: Dhoha Dhieb, et al.
Published: (2019-05-01)

Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas
by: Gonzaga Isabela Martins, et al.
Published: (2012-12-01)

Oncogenic driver mutations in Vietnamese patients with lung adenocarcinoma
by: Linh Dieu Vuong, et al.
Published: (2023-08-01)

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations
by: Xiaodan Yang, et al.
Published: (2021-10-01)

PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK‐rearranged lung cancer
by: Sarang S. Talwelkar, et al.
Published: (2023-05-01)

Editorial: Molecular genetic testing and emerging targeted therapies for non-small cell lung cancer
by: Carlos Gil Ferreira, et al.
Published: (2023-11-01)

Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
by: Alessia Pellerino, et al.
Published: (2021-06-01)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
by: Haoyue Hu, et al.
Published: (2023-08-01)

A Real-World Molecular Epidemiological Study of Non-Small-Cell Lung Cancer (NSCLC) Patients from Western India
by: Ashish Joshi, et al.
Published: (2023-07-01)

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations
by: Antonio Passaro, et al.
Published: (2021-04-01)

Editorial: Precision Medicine in Pulmonary Diseases—Same Principles, New Approach
by: Paula Tejera, et al.
Published: (2021-12-01)

Prevalence of <it>KRAS</it>, <it>BRAF</it>, and <it>PIK3CA</it> somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
by: Palomba Grazia, et al.
Published: (2012-08-01)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-07-01)

Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients
by: Liu J, et al.
Published: (2019-05-01)

Primary Melanoma of the Lung: A Systematic Review
by: Panagiotis Paliogiannis, et al.
Published: (2020-10-01)

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study
by: Hongge Liang, et al.
Published: (2019-07-01)

Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis
by: Michelle Bradbury, et al.
Published: (2022-01-01)

RESISTANCE TO TARGETED THERAPIES IN MELANOMA: NEW INSIGHTS
by: Giuseppe Palmieri, et al.
Published: (2013-12-01)